RxDoctor Payments Data

Cheryl Roberson, MD

Family Medicine · Wesley Chapel, FLNPI 1225145147

Payments from drug & device makers

$898in general payments, 2019–2025

Across 32 payments — averaging $28.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$381
  • Boston Scientific$144
  • Dexcom, Inc.$90
  • Bayer$83
  • Lilly USA, LLC$58
  • Abbott$55
  • plus $88 from 4 others

What the payments were for

  • Food & beverage$898100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$898 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$102,568
Medicare patients
189
Services billed
1,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$90,407
MounjaroTirzepatide61$76,561
FarxigaDapagliflozin Propanediol37$43,586
TrulicityDulaglutide23$38,990
JardianceEmpagliflozin21$36,402
EliquisApixaban36$35,533
RybelsusSemaglutide23$25,642
JanuviaSitagliptin Phosphate11$11,755
LinzessLinaclotide12$10,351
Rosuvastatin Calcium238$3,543
Albuterol Sulfate HfaAlbuterol Sulfate87$2,475
SynthroidLevothyroxine Sodium25$2,268
Atorvastatin Calcium236$1,894
ValacyclovirValacyclovir Hcl17$1,789
Losartan Potassium167$1,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$381$116,04895 claims
Lilly USA, LLCMounjaro, Trulicity$58$115,55184 claims
AstraZenecaFarxiga$35$43,58637 claims
Boehringer IngelheimJardiance$17$36,40221 claims
MerckJanuvia$13$11,75511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →